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Introduction
Left ventricular hypertrophy (LVH) is an important
prognosticator for cardiovascular (CV) risk in persons
with and without arterial hypertension. Given the high
prevalence of these conditions, LVH screening is man-
datory for CV prevention. Although not evaluated in a
middle aged preventive medicine population, Electrocar-
diography (ECG) is widely used for LVH screening.
Although not widely accessible as a screening technique,
cardiovascular magnetic resonance (CMR) offers a
unique opportunity to calculate LV mass index (LVMI)
as the gold standard for other diagnostic tests.
Purpose
T oa s s e s st h er e l i a b i l i t yo fE C GL V Hc r i t e r i ac o m p a r e d
to CMR ventriculometry (cutoff: LVMI 83 g/m
2)a n d
the incremental value of CMR in a population from a
prevention programme.
Methods
220 (206 male, age 49.5 ± 8,4 years) consecutive partici-
pants of a prevention programme without known heart
disease underwent CMR in a 1.5 T scanner (Magnetom
Avanto, Siemens, Erlangen, Germany) including SSFP
Cine (TrueFISP TR 3ms, TE 1.5 ms, FA 72°, slice thick-
ness 6 mm) and delayed enhancement imaging.
LVMI was derived from contiguous short axis cine
images using the summation of discs method. These
data were compared to Sokolow-Lyon amplitude, Soko-
low-Lyon duration product, Cornell amplitude, Cornell
duration product, and Romhild-Estes score (Tables 1,2)
in 12 lead ECG.
Results
31 participants had positive LVH criteria in ECG, of
which 6, and 4 ECG negatives, showed LVH (LVMI >
83 g/m
2) in CMR (Figure 2). All ECG criteria were posi-
tively correlated with LV mass (Table 3). Specificities
and negative predictive values were high in our low-
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Table 1 Calculation of the ECG criteria
Criterion Calculation Normal
value
Sokolow-Lyon Amplitude (mV) SV1 + RV5/V6 <3,5
Sokolow-Lyon Duration Product
(mm * ms)
(SV1 + RV5/V6) * QRS
duration
<2940
Cornell Amplitude (mV) R aVL + SV3 <2,8
Cornell Duration Product
(mm + ms)
(R aVl + SV3) * QRS
duration
<2440
Table 2 Romhild Estes Score
Criterion Points
Ro rS>2 0m m
or
Si nV 1o rV 2>3 0m m
or
Ri nV 5o rV 63 0m m
3
ST/T changes typical of LVH, taking digitalis 1
ST/T changes typical of LVH, not taking digitalis 3
P terminal force in V1 1mm or more, duration >40 ms 3
Left axis deviation > -30° 2
QRS dura> 90 ms 1
Intrinsicoid deflection in V5 or V6 >50 ms 1
Eberle et al. Journal of Cardiovascular Magnetic Resonance 2011, 13(Suppl 1):P244
http://jcmr-online.com/content/13/S1/P244
© 2011 Eberle et al; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Figure 2 CMR showing LVH with increased LVMI and septal thickness, in a patient with pathologic Sokolow-Lyon Index, Sokolow Duration
Product, and REPSS.
Table 3 Diagnostic characteristics and correlation with LVMI of the ECG criteria
Criterion Correlation Coefficient (Perason) Sensitivity Specificity Posisitive Predictive Value Negative Predictive Value
Sokolow-Lyon Amplitude 0.413 0.52 0.94 0.26 0.98
Sokolow-Lyon Product 0.436 0.44 0.92 0.18 0.92
Cornell Amplitude 0.224 0.111 0.97 0.14 0.95
Cornell Product 0.231 0.2 0.97 0.11 0.96
REPSS 0.248 0.22 0.93 0.12 0.97
Figure 1 ROC analysis of the ECG criteria to identify LVH
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dictive values were poor (Table 3, Figure 1).
Conclusions
CMR identified a large proportion of false positive ECG
results (25/31), and identified additional LVH cases
(4/189). ECG is not a reliable LVH screening tool in a
middle aged prevention population. LVH screening
should be based on imaging techniques.
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